Tivozanib (Fotivda) significantly improved progression-free survival (PFS), compared with sorafenib (Nexavar), in patients with highly relapsed or refractory metastatic renal cell carcinoma (RCC), according to results from the phase III TIVO-3 trial presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.1-2
“We believe the TIVO-3 data demonstrate a favorable risk/benefit profile for tivozanib in the growing population of patients who have relapsed or become refractory to multiple lines of therapy, including checkpoint inhibitors,” Sumanta Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, and co-director, Kidney Cancer Program, at City of Hope Comprehensive Cancer Center, said in a press release.2
Final OS hazard ratio (HR) was 0.97 (95% CI, 0.75-1.24; P= .78). An updated analysis of the data…
